Conversely, a phase 2, double-blind, multicenter randomized trial carried out on gMG patients, who were all AChR-MG except for two MuSK-MG patients, showed no statistically significant differences in the primary endpoint (i.e. mean change in the Quantitative Myasthenia Gravis, QMG, score) between placebo and active treatment after 24 weeks (74) (Table 1). The gene discussed is MUSK; the disease is myasthenia gravis.